Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Compugen (Nasdaq:CGEN), a clinical-stage cancer immunotherapy company using AI/ML for computational target discovery, will present at the 2026 Stifel Virtual Targeted Oncology Forum.

Rhea-AI Summary

Compugen (Nasdaq:CGEN), a clinical-stage cancer immunotherapy company using AI/ML for computational target discovery, will present at the 2026 Stifel Virtual Targeted Oncology Forum.

The management presentation is scheduled for May 19, 2026, 10:00–10:25 AM ET, with live webcast and replay via Compugen’s investor relations website.

Argus May 12 session

-1.39% close to close Open Argus

Details

News Market Reaction – CGEN

In the May 12 session, CGEN declined 1.39%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Compugen’s participation in the 2026 Stifel Virtual Targeted Oncology F...

Analysis

This announcement highlights Compugen’s participation in the 2026 Stifel Virtual Targeted Oncology Forum on May 19 from 10:00–10:25 AM ET, continuing a pattern of active conference engagement. A live and replay webcast supports ongoing investor outreach. In recent months, financial results on Mar 2, 2026 and multiple conference appearances have been central catalysts, so investors may track how future data releases and clinical updates complement these visibility events.

Key Figures

Event date: May 19, 2026 Presentation time window: 10:00–10:25 AM ET Current price: $2.87 +5 more

Event date

May 19, 2026

Date of Stifel Virtual Targeted Oncology Forum presentation

Presentation time window

10:00–10:25 AM ET

Scheduled slot at 2026 Stifel Virtual Targeted Oncology Forum

Current price

$2.87

Pre‑news close for CGEN

52‑week high

$3.235

Upper end of 52‑week trading range before this news

52‑week low

$1.26

Lower end of 52‑week trading range before this news

Market cap

$274,206,968

Equity value prior to forum participation announcement

Today’s volume

443,658 shares

Compared with 20‑day average volume of 557,765 shares

Publication date

May 12, 2026

Date of press release about forum participation

Historical Context

5 past events · Latest: May 04

5 events

1. May 04

   Earnings date notice

   24h Move

   -2.6%

   Announcement of upcoming Q1 2026 results and conference call schedule.

2. Apr 09

   Conference participation

   24h Move

   +8.3%

   Plan to present at Needham virtual healthcare conference with webcast access.

3. Mar 02

   Earnings and update

   24h Move

   +24.3%

   Reported FY 2025 results, cash position, royalty monetization and clinical progress.

4. Feb 19

   Multiple conferences

   24h Move

   +5.3%

   Participation in two late‑Feb and early‑Mar 2026 investor healthcare conferences.

5. Feb 17

   Earnings date notice

   24h Move

   +1.8%

   Scheduled release date and call for Q4 and FY 2025 financial results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

immunotherapy, ai/ml

2 terms

immunotherapy medical

"a clinical-stage cancer immunotherapy company and a pioneer in computational"

Treatment that uses or enhances the body’s immune system to detect and fight disease, most often cancers or chronic infections; think of it as training or arming the body’s own soldiers to find and destroy targets. It matters to investors because successful immunotherapies can lead to high-value drug approvals, recurring revenue from long-term treatments, and changes in competitive dynamics, while failures or safety issues in clinical trials can materially affect company valuations.

ai/ml technical

"computational target discovery powered by AI/ML, today announced that management"

AI/ML stands for artificial intelligence and machine learning, software systems that identify patterns in data and make predictions or automate decisions, improving performance as they process more information. Investors care because these technologies can boost revenue, cut costs and create competitive advantages — like a factory that learns to produce goods faster and with fewer mistakes — while also introducing execution, ethical and regulatory risks that can affect a company’s value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOLON, Israel, May 12, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present at the 2026 Stifel Virtual Targeted Oncology Forum. The presentation will take place on Tuesday, May 19, 2026, at 10:00-10:25 AM ET.

A live webcast will be accessible on the Investor Relations section of the Compugen website at www.cgen.com. A replay will also be available following the live event.

About Compugen 
Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen^™, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, and COM902, an anti-TIGIT antibody, have been evaluated for the treatment of solid tumors as monotherapy and in combinations. Currently, Compugen is conducting a blinded randomized ovarian cancer platform trial evaluating COM701 as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902 program, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, Compugen's has an early-stage immuno-oncology pipeline consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company contact:
Investor relations
Email: ir@cgen.com
Tel: +1 (628) 241-0071 

View original content:https://www.prnewswire.com/news-releases/compugen-to-participate-in-2026-stifel-virtual-targeted-oncology-forum-302769368.html

SOURCE Compugen Ltd.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Compugen (CGEN) present at the 2026 Stifel Virtual Targeted Oncology Forum?

Compugen will present on May 19, 2026, from 10:00 to 10:25 AM ET. According to Compugen, the company’s management will participate in the virtual forum to discuss its activities in clinical-stage cancer immunotherapy.

How can investors watch Compugen’s (CGEN) presentation at the 2026 Stifel Virtual Targeted Oncology Forum?

Investors can watch the presentation via a live webcast on Compugen’s investor relations section at www.cgen.com. According to Compugen, a replay of the virtual session will also be available online after the live event concludes.

What type of company is Compugen (CGEN) presenting at the 2026 Stifel Virtual Targeted Oncology Forum?

Compugen is a clinical-stage cancer immunotherapy company focused on computational target discovery powered by AI and machine learning. According to Compugen, this technology underpins its oncology pipeline, which will be highlighted during the targeted oncology virtual forum.

Why is Compugen’s (CGEN) participation in the 2026 Stifel Virtual Targeted Oncology Forum relevant for investors?

The forum offers investors direct insight into Compugen’s cancer immunotherapy strategy and management commentary. According to Compugen, the webcast and replay provide accessible updates on its AI/ML-driven target discovery platform and ongoing clinical-stage efforts in oncology.